AACE In the news

January 6, 2026 | NPR News

Wegovy Pill Now Available at Pharmacies

The weight loss medication Wegovy is now available as a pill. In an NPR report, AACE Past President Scott D. Isaacs, MD, FACP, FACE, emphasizes the importance of careful patient education, noting that the medication must be taken exactly as directed to be effective. Listen to the full interview on NPR News.

January 2, 2026 | Doc Wire News

Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes With Superior Metabolic and Renal Benefits in Type 2 Diabetes

The long‑awaited results of SURPASS‑CVOT were recently published in the New England Journal of Medicine, marking a major advance in the evidence base for incretin‑based therapy for patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). AACE Past President Scott D. Isaacs, MD, FACP, FACE, highlights that this was the first randomized, prospective cardiovascular outcomes trial to show that tirzepatide delivers cardiovascular benefits that extend beyond glycemic control and weight reduction in a high‑risk secondary‑prevention population. Read the full article on Doc Wire News to learn more.

December 23, 2025 | Medscape

Turning the Tide in Type 2 Diabetes: Evidence-Based Pathways to Remission

In a Medscape review on type 2 diabetes remission, AACE President Scott D. Isaacs, MD, FACP, FACE, emphasized that remission is not the same as reversal and highlighted growing evidence that sustained lifestyle changes and modern therapies, including GLP-1 receptor agonists, can help some patients achieve and maintain remission with ongoing monitoring.

December 23, 2025 | Healio

FDA Approves Wegovy Pill, the First Oral GLP-1 to Treat Obesity

Following FDA approval of the first oral GLP-1 for obesity, AACE President Scott D. Isaacs, MD, FACP, FACE, called the Wegovy pill one of the most important developments in endocrinology in 2025, noting that an oral option expands access to effective obesity treatment while requiring careful attention to dosing and tolerability. Learn more by reading the full article on Healio.

December 16, 2025 | Everyday Health

Reversing Prediabetes Could Slash Heart Disease Risk

According to new research, people with prediabetes who lower blood sugar to normal levels cut their heart disease risk in half. AACE President Scott D. Isaacs, MD, FACP, FACE, highlights that achieving prediabetes remission through structured lifestyle changes can significantly reduce the risk of heart attack and heart failure. The findings reinforce the importance of knowing your exact numbers and working with a clinician to normalize glucose as a measurable, meaningful goal for long-term cardiovascular health.

December 3, 20205 | Medscape

Hearing Loss: A Silent Complication of Diabetes

A new review published in Otolaryngology-Head and Neck Surgery reports that individuals with type 2 diabetes face a significantly elevated risk of hearing loss, particularly at higher frequencies. AACE President Scott D. Isaacs, MD, FACP, FACE, explains that adults with diabetes have an increased risk of hearing loss because high blood sugar damages the small blood vessels that supply the inner ear, leading to poor blood flow and nutrient delivery, which causes the delicate hair cells of the cochlea to deteriorate and results in sensorineural hearing loss, especially at higher frequencies. An important take-home message of the study is that hearing loss should be recognized as a microvascular complication of diabetes, for which screening and early detection are warranted as part of comprehensive diabetes care. Learn more by reading the full article on Medscape.

December 2, 2025 | MedCentral

New AACE Adiposity-Based Chronic Disease Algorithm Redefines Obesity Assessment and Care

AACE released a new consensus update to its Adiposity Based Chronic Disease (ABCD) Algorithm, enhancing the 2016 guidance with a stronger focus on complication centric, person centered care. Rather than prioritizing weight loss alone, the update emphasizes improving overall health outcomes and recognizing obesity as a chronic disease shaped by adiposity, associated complications, and underlying pathophysiology. AACE President Scott D. Isaacs, MD, FACP, FACE, notes that the ABCD framework offers a practical, patient-centered method for diagnosing and treating obesity by focusing on health impact rather than weight alone. AACE member and guideline co-author Timothy Garvey, MD, MACE, highlights key updates including 11 clinical algorithms, greater emphasis on waist-to-height ratio, weight-reduction targets correlated to clinical improvement, and the integration of psychosocial and social determinants of health into individualized treatment plans. The consensus also reinforces the need for lifelong obesity management and treatment intensity based on disease stage and complication severity. Learn more by reading the full article on MedCentral.

October 28, 2025 | Pharmaceutical Technology

GLP-1RA Microdosing Trend Continues Despite “Anecdotal Evidence”

Found Health has become the latest telehealth company to offer a microdosing program with weight loss jabs, despite an absence of peer-reviewed scientific evidence that shows microdosing GLP-1RA drugs is effective or safe. AACE President Scott D. Isaacs, MD, FACP, FACE, emphasized that AACE does not support the routine use of microdosing GLP-1RA medications in clinical care and recommends adherence to FDA-approved dosing guidelines for these agents. Learn more in the full article on Pharmaceutical Technology.

October 30, 2025 | Health Monitor

When Weight Bias Intersects With Ageism

According to the CDC, obesity affects roughly two in five Americans aged 60 and older, putting this population at greater risk for cardiovascular and metabolic diseases and a decreased quality of life. In the article When Weight Bias Intersects With Ageism (page 17), Scott Isaacs, MD, FACP, FACE, President of AACE, explains how misconceptions about aging and obesity can lead to undertreatment. He emphasizes that obesity is a medical condition at any age and clinicians should address weight bias and ageism to ensure inclusive, patient-centered care for older adults.

October 7, 2025 | NPR News

Patients Turn to ‘Gray Market’ for Cheaper Obesity Drugs, but It’s Risky

An NPR report explores how some patients are turning to the gray market to buy raw ingredients for obesity medications as a cheaper alternative to prescription drugs. AACE President Scott D. Isaacs, MD, FACP, FACE, warns about the risks of getting contaminated or counterfeit products, including infections, dosing errors, and lack of effectiveness.

October 6, 2025 | Medscape

When ‘Diet’ Foods Sabotage Weight Loss: A Physician’s Guide to Patient Education

Many patients striving for weight loss turn to products marketed as “diet products” or labeled as healthy alternatives, but these options can often do more harm than good. AACE President Scott D. Isaacs, MD, FACP, FACE, explains how ultraprocessed foods can undermine healthy weight management. Learn more by reading the full article on MedScape.

October 2, 2025 | Firstpost

Weight Loss Drugs: Should You Take Them or Not?

Indian regulators have approved weight loss drug Ozempic for use in the Indian market. The move comes amid a raging craze around such medicines, billed as a "miracle" by some. How do weight loss drugs work? Who should be taking them? What are the risks? AACE President Scott D. Isaacs, MD, FACP, FACE, discusses these with Firstpost's Prathik S Vinod.

September 23, 2025 | DocWireNews

GLP-1 Therapies and Cancer Prevention: Metabolic Dysfunction as the Key Determinant

A recent JAMA Oncology study shows that GLP-1 medications (liraglutide, semaglutide, tirzepatide) may reduce cancer risk in adults with obesity by 17%. The greatest reductions were seen in endometrial, ovarian, and meningioma cancers. AACE President Scott D. Isaacs, MD, FACP, FACE, explains that these findings highlight the role of metabolic dysfunction, particularly MASLD, as a key driver of cancer risk. Therapies like semaglutide have already demonstrated efficacy in reversing MASLD/MASH, establishing their role as foundational treatments in the evolving landscape of metabolic medicine.

September 20, 2025 | Men's Fitness

Daily GLP-1 Pills Could Reshape Weight Loss

Drugmakers are racing to bring once-daily GLP-1 weight-loss pills to market, potentially offering a more convenient alternative to weekly injections. AACE President Scott D. Isaacs, MD, FACP, FACE, notes that having another option to switch to may be appealing for many patients. Learn more by reading the article on Men's Health.

September 18, 2025 | The Wall Street Journal

The Promise and Hurdles of the New Weight-Loss Pills

An intriguing new option is emerging for weight-loss treatment: a once-daily pill instead of weekly injections. AACE President Scott D. Isaacs, MD, FACP, FACE, explained that many patients have tried other agents that either didn’t work or caused side effects, and having another option to switch to will be appealing for a lot of people. Learn more in the full article from The Wall Street Journal.

September 3, 2025 | Medscape

An Overlooked Connection: How Diabetes Can Contribute to Knee Pain and What to Do About It

Knee pain is a common but often overlooked symptom in individuals with diabetes. AACE President Scott D. Isaacs, MD, FACP, FACE, explains that while many patients and clinicians focus on classic complications such as neuropathy or numbness in the feet, diabetes can also affect the joints, including the knees. He recommends routinely screening for musculoskeletal symptoms during diabetes appointments. By taking a complications-centric approach that includes early recognition, patient education, lifestyle modification, and multidisciplinary care, we can better support patients in addressing knee pain related to diabetes. Learn more by reading the full article on Medscape.

September 2, 2025 | MedCentral

GLP-1RA Drugs Show Cancer-Protective Potential in Obesity

A new JAMA Oncology study found that Individuals with obesity taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) demonstrated 17% lower cancer risk compared to non-users. AACE President Scott D. Isaacs, MD, FACP, FACE, explained that the findings suggest GLP-1 medications may be associated with decreased cancer risk in people with obesity, while noting that observational data show association rather than causation and that longer-term studies in high-risk MASLD patients are needed. He added that GLP-1RA medications may represent a comprehensive therapeutic approach in metabolic medicine, treating multiple diseases simultaneously. Learn more by reading the full article on MedCentral.

August 25, 2025 | Healthline

Serena Williams Lost 31 Pounds on GLP-1 Drug Zepbound: What to Know

Serena Williams is opening up about her weight loss journey with GLP-1 medication Zepbound, helping to change the conversation around obesity care. AACE President Scott D. Isaacs, MD, FACP, FACE, explains that obesity is a disease and GLP-1 medications are effective therapies that work best when combined with healthy habits and ongoing medical supervision. Learn more by reading the full article on Healthline.

August 19, 2025 | Everyday Health

People With Weight-Related Chronic Liver Disease Have a New Treatment Option

The FDA has expanded Wegovy use to include adults with metabolic-associated steatohepatitis (MASH) and moderate to severe fibrosis, or scarring in the liver. AACE President Scott D. Isaacs, MD, FACP, FACE, explained that semaglutide acts on the brain’s appetite regulation center to decrease appetite and reduce cravings, leading to significant, sustained weight loss that in turn improves insulin sensitivity, decreases liver fat, and can reverse the inflammation and cellular injury in MASH. Learn more by reading the full article on Everyday Health.

August 18, 2025 | Healio

FDA Approves Wegovy for Certain Adults With Noncirrhotic MASH

The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. AACE President Scott D. Isaacs, MD, FACP, FACE, noted this major advancement highlights the urgency of expanding screening and implementing multidisciplinary care, as MASH remains highly prevalent and often underdiagnosed, particularly in people with diabetes and other cardiometabolic risk factors. Read the full article on Healio.